IQVIA Holdings Inc. $IQV Shares Purchased by Northwestern Mutual Wealth Management Co.

Northwestern Mutual Wealth Management Co. lifted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 3.0% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 356,505 shares of the medical research company’s stock after purchasing an additional 10,317 shares during the quarter. Northwestern Mutual Wealth Management Co.’s holdings in IQVIA were worth $68,884,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the business. Korea Investment CORP purchased a new stake in IQVIA during the second quarter valued at about $13,918,000. BlackRock Inc. acquired a new position in shares of IQVIA in the 2nd quarter valued at about $2,811,292,000. Deutsche Bank AG purchased a new stake in shares of IQVIA during the 2nd quarter worth about $143,074,000. Focus Partners Advisor Solutions LLC acquired a new stake in IQVIA during the 2nd quarter worth approximately $976,000. Finally, Pallas Capital Advisors LLC acquired a new stake in IQVIA during the 2nd quarter worth approximately $1,552,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

IQV has been the subject of several research reports. HSBC reiterated a “buy” rating and set a $240.00 price objective on shares of IQVIA in a research note on Monday, July 6th. Wall Street Zen cut shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Saturday. Deutsche Bank Aktiengesellschaft set a $240.00 price objective on IQVIA in a research note on Thursday, July 9th. Barclays reaffirmed an “overweight” rating on shares of IQVIA in a research report on Tuesday, July 28th. Finally, Mizuho raised their target price on IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $241.88.

IQVIA Stock Performance

Shares of IQV opened at $258.39 on Wednesday. The firm has a market cap of $42.53 billion, a price-to-earnings ratio of 32.06, a PEG ratio of 2.23 and a beta of 1.18. The business’s 50 day moving average is $225.75 and its two-hundred day moving average is $190.73. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. IQVIA Holdings Inc. has a 52-week low of $154.50 and a 52-week high of $265.25.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping the consensus estimate of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The business had revenue of $4.37 billion for the quarter, compared to analysts’ expectations of $4.30 billion. During the same quarter last year, the company posted $2.81 earnings per share. The company’s quarterly revenue was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Analysts forecast that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA announced that its Board of Directors has authorized a share buyback plan on Thursday, May 7th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s management believes its shares are undervalued.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Bhavik Patel sold 1,855 shares of the firm’s stock in a transaction dated Friday, July 31st. The shares were sold at an average price of $235.27, for a total value of $436,425.85. Following the transaction, the insider owned 1,348 shares of the company’s stock, valued at $317,143.96. This trade represents a 57.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Eric Sherbet sold 5,000 shares of the firm’s stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total value of $1,245,800.00. Following the completion of the sale, the insider owned 20,999 shares in the company, valued at $5,232,110.84. The trade was a 19.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 12,913 shares of company stock worth $3,098,793 in the last quarter. 1.70% of the stock is currently owned by corporate insiders.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.